Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Minnesota Attorney General Keith Ellison on Monday will share a major development in his lawsuit against three of the biggest ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. Warren Buffett Sold Over $134 Billion Worth of Stock in 2024, But His Most Recent $200 Million in ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...